Stephens Investment Management Group LLC
Position in PTGX — Protagonist Therapeutics, Inc
CIK 1314440
LITTLE ROCK, AR
Position in PTGX
as of Jun 30, 2026
· filed Jul 29, 2026
Position Value
$34,546,966
New position
Shares Held
281,832
first reported quarter
Ownership
0.436%
of shares outstanding
% of Portfolio
0.37%
of 13F equity value
Holder Rank
#40
of 341 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 0%
Shared 96%
None 4%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Stephens Investment Management Group LLC holds $614,628,718 across 6 Biotechnology names. PTGX ranks #6 (5.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LGND |
Ligand Pharmaceuticals Inc
|
475,609 | $150,335,248 | |
| 2 | EXEL |
Exelixis, Inc.
|
2,710,011 | $147,451,698 | |
| 3 | HALO |
Halozyme Therapeutics, Inc.
|
1,392,819 | $109,015,943 | |
| 4 | TVTX |
Travere Therapeutics, Inc.
|
1,875,304 | $106,536,020 | |
| 5 | TECH |
BIO-TECHNE Corp
|
944,697 | $66,742,843 | |
| 6 | PTGX |
Protagonist Therapeutics, Inc
This page
|
281,832 | $34,546,966 |
All Filings in PTGX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $34,546,966 | 281,832 | Shares | Defined | 2026-07-29 | |
| No filing history on record for this holder in this stock. | ||||||